Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Macrolide-containing micro-capsules

A technology of macrolide and microcapsules, which is applied in the direction of chemicals for biological control, plant growth regulators, fungicides, etc., and can solve the problem of not prompting emulsifiable activity of emulsifiable oil

Inactive Publication Date: 2016-09-28
FMC CORP
View PDF4 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Referring to the above-mentioned paper of Yang Kai, those skilled in the art will try to use complex coacervate (gelatin and gum arabic) as the best solution, and it still can only obtain the effective encapsulation of 65% of abamectin in microcapsules
On the other hand, according to Yuan Quing-mei's report, the encapsulation rate is still only 83.24%, and there is no suggestion to imitate the activity of emulsifiable cream at high encapsulation rate (eg, over 90% in our invention)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Macrolide-containing micro-capsules
  • Macrolide-containing micro-capsules
  • Macrolide-containing micro-capsules

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 2

[0084] Example 2 - Sustained Release Formulation

[0085]The present invention can take advantage of the UV protective synergistic activity of the formulation ingredients, their chemical compatibility with the mectins, their demonstrated sufficient biological activity and their good physicochemical properties for sustained release formulations of the mectins. This preparation is an embodiment of the present invention in terms of macrolide slow-release, and the mibaycin (milbemycin A 3 and A 4 ) and Abamectin (Abamectin B 1a and B 1b ) microencapsulation is illustrated.

[0086] Formulation of Example 2.A

[0087]

[0088] The formulations according to the invention meet the stated requirements and show increased UV protection compared to the conventional EC formulations of Abamectin and Mibamectin detailed below (comparative formulations), and of course also compared to prior art formulations Improved particle size uniformity and physical stability of the formulation. ...

Embodiment 3

[0092] Example 3 - Encapsulation levels of mectins compared to similar methods of the prior art

[0093] A formulation very similar to the formulation claimed in the invention and method was prepared for comparison according to the method of the invention and using the following formulation.

[0094] Formulation 3.A

[0095]

[0096] Formulation 3.B

[0097] Preparation 3.B of the present invention is the same as Example 1.A, except that abamectin is replaced by ivermectin.

[0098] The encapsulation level of pure ivermectin in formulation 3.A (microencapsulated based on the same reaction as our invention) was only 61%, while that of 3.B was 94.7%. This demonstrates that the degree of microencapsulation of the present invention is superior to that of conventional polyurea / polyurethane microencapsulation. We purposefully chose 3A because it is a close modification of the published microencapsulation method for the insecticide clomazone (which has been shown to control vol...

Embodiment 4

[0099] Example 4 - Mixed formulation of microencapsulated macrolides and suspended neonicotinoids

[0100] As detailed in the description, the present invention provides for any possible combination of active ingredients as long as there is no incompatibility (chemical and / or physicochemical). A representative example is the combination of 15% suspension concentrate of imidacloprid and thiamethoxam (ratio 1:1 wt.-%) and 3% microencapsulated abamectin.

[0101] To carry out this combination, a suspension concentrate of imidacloprid and thiamethoxam with the target concentrations is first prepared by any prior art method. Then prepare the microencapsulated formulation of Abamectin according to embodiment 1.A, wherein the active ingredient is increased accordingly and the same amount of water is reduced. In the microencapsulation formulation of Abamectin, add any necessary surfactant in addition so that microcapsules are well dispersed in the suspending agent (for example, 1:1:1...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to microcapsules comprising the macrolides abamectin, mibamectin, milbemycin, emamectin, ivermectin and generally mectins, wherein the active ingredients are protected from UV degraded, with specific release profile similar to emulsifiable concentrates or if desired with long acting; also with suitable rheological properties and reduced toxicity. The present invention provides a unique microencapsulation method for the chemical stability and biological activity of mectins such as abamectin and provides for CS, WG / CS, ZC, EC / CS formulations and any formulation comprising microcapsules Mectins microcapsules in type and in combination with other biologically active ingredients.

Description

[0001] This application is the title of invention submitted on August 7, 2009 "comprising macrolide avermectin, mibaycin, abamectin, milbemycin, emamectin, ivermectin and general A divisional application of the Chinese patent application 200980161833.3 for microcapsules of mectins. technical field [0002] The present invention relates to microbial origin (preferably from Streptomyces avermitilis (Streptomyces avermitilis), Streptomyces spp.), or synthetic or DNA recombinant origin including abamectin, ivermectin, milbemyces Microencapsulation of macrolides including milbemycin (eg milbemicyn oxime), emamectin (eg emamectin benzoate). Background technique [0003] The actinomycete Streptomyces avermitilis produces a series of chemically related compounds characterized by helminticidal, acaricidal, scabicidal and insecticidal properties, the abamectins (trade name: Abamectin, which is abamectin A mixture of B1a and abamectin B1b) is the most representative class. Reports on...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A01N25/04A01N25/28A01N25/22A01N43/90A01N51/00A01N53/08A01P7/04A01P7/02A01P3/00A01P1/00A01P21/00
Inventor V·卡萨纳希尔内M·西梅诺谢拉B·西梅诺谢拉
Owner FMC CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com